📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-17 16:46
646 analysed today
646
Today
133,535
All-time analysed
40,118
Positive
6,284
Negative
79,315
Neutral
7,750
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
7 announcements match the current filters (relevance ≥ 5).
CARE Upgrades Fermenta Biotech's Long-Term Rating to BBB+; Total Facilities at Rs 172.98 Cr
Fermenta Biotech Limited has received a credit rating upgrade from CARE Ratings Limited across its bank facilities totaling Rs 172.98 crore. Long-term bank facilities of Rs 166.73 crore (enhanced from Rs 118.94 crore) were upgraded to CARE BBB+; Stable from CARE BBB; Stable. Short-term bank facilities of Rs 6.25 crore were upgraded to CARE A2 from CARE A3+. The rating enhancement indicates improved operational and credit profile, potentially aiding in better borrowing terms.
Confidence: HIGH
What changedCARE Ratings upgraded Fermenta Biotech's long-term rating to BBB+ (from BBB) and short-term rating to A2 (from A3+), alongside enhancing long-term limits.
Why it mattersA higher credit rating lowers credit risk perception, improves borrowing terms, and provides enhanced liquidity headroom via increased bank facility limits.
Total rated facilities: Rs. 172.98 croreLong-term facilities: Rs 166.73 crorePrevious long-term limit: Rs 118.94 croreShort-term facilities: Rs 6.25 croreRevised Long-term Rating: CARE BBB+; StableRevised Short-term Rating: CARE A2
📅 Short termPositive sentiment driver reflecting rating agency confidence in the company's financial stability.
📈 Long termStrengthens financial flexibility and may lower the weighted average cost of debt over coming quarters.
Key Highlights
Long-term bank facilities rating upgraded to CARE BBB+; Stable from CARE BBB; Stable
Long-term bank facilities limit enhanced to Rs 166.73 crore from Rs 118.94 crore
Short-term bank facilities of Rs 6.25 crore upgraded to CARE A2 from CARE A3+
Total rated bank facilities increased to Rs 172.98 crore
👀 What to Watch
Track subsequent quarterly results to see if the rating upgrade helps optimize finance costs, and monitor debt utilization against enhanced limits.
₹3.75 Dividend and ₹100 Cr Related Party Transaction Approved at Fermenta Biotech AGM
Fermenta Biotech Limited held its 74th Annual General Meeting on August 11, 2026, where shareholders approved a dividend of ₹3.75 per share (75% of face value). A key resolution passed includes the approval of material related party transactions with its step-down subsidiary, Fermenta USA LLC, for an aggregate value up to ₹100 crores. The company also authorized the payment of commissions to non-executive directors, capped at 1% of net profits. All proposed resolutions, including the re-appointment of Director Ms. Rajeshwari Datla, were passed with the requisite majority.
Confidence: HIGH
What changedShareholders have formally ratified the dividend payout and established a ₹100 crore ceiling for transactions with the company's US-based subsidiary.
Why it mattersThe approval of a ₹100 crore transaction limit with Fermenta USA LLC indicates the scale of expected business or financial support for international operations, while the dividend confirms the company's commitment to shareholder returns.
Dividend per share: ₹3.75Dividend percentage: 75%RPT Limit (Fermenta USA LLC): ₹100 croresDirector Commission Cap: 1% of net profitsDividend Payment Date: August 21, 2026
📅 Short termThe stock may see minor price adjustments as the dividend payment date of August 21 approaches.
📈 Long termLimited structural impact; however, the significant transaction limit for the US subsidiary suggests a strategic focus on expanding or maintaining a large presence in the American market.
⚠ Risk flags
- Related party transactions (₹100 cr) carry the risk of transfer pricing scrutiny or potential conflicts of interest.
Key Highlights
Approved a dividend of ₹3.75 per equity share (75% of ₹5 face value) for FY 2025-26.
Authorized material related party transactions with Fermenta USA LLC up to a limit of ₹100 crores.
Capped commissions for Non-Executive Directors at 1% of the company's net profits.
Set the dividend payment deadline for on or before August 21, 2026.
Confirmed the re-appointment and continuation of Ms. Rajeshwari Datla as a Non-Executive Director.
👀 What to Watch
Investors should monitor the upcoming quarterly results to see how the ₹100 crore transaction limit with the US subsidiary translates into revenue growth or operational expansion in that market.
Fermenta Biotech Approves ₹3.75 Dividend and ₹100 Cr Related Party Transaction at 74th AGM
Fermenta Biotech Limited held its 74th Annual General Meeting on August 11, 2026, where shareholders approved a dividend of ₹3.75 per share (75% of face value) for FY26. A significant resolution was passed for material related party transactions with its step-down subsidiary, Fermenta USA LLC, for an aggregate value up to ₹100 crores. The board also received approval to distribute commissions to Non-Executive Directors up to 1% of net profits. The dividend is scheduled for payment by August 21, 2026, to shareholders on record as of August 05, 2026.
Confidence: HIGH
What changedShareholders have formally ratified the financial results for FY26, the dividend payout, and the operational limits for transactions with the US subsidiary.
Why it mattersThe approval of the ₹100 crore transaction limit with the US subsidiary indicates the scale of international business support or trade expected in the coming year.
Dividend per share: ₹3.75Dividend percentage: 75%RPT Limit (Fermenta USA LLC): ₹100 croresDirector Commission Limit: 1% of net profitsDividend Record Date: August 05, 2026Dividend Payment Deadline: August 21, 2026
📅 Short termThe stock may see minor activity around the dividend payment date of August 21, though the record date has already passed.
📈 Long termThe continued support and transaction volume with the US subsidiary will be a key factor in the company's international growth strategy.
⚠ Risk flags
- Material related party transactions with a step-down subsidiary (₹100 crores).
Key Highlights
Approved dividend of ₹3.75 (75%) per equity share of ₹5 face value for FY2025-26.
Authorized material related party transactions with Fermenta USA LLC up to ₹100 crores.
Approved commission for Non-Executive Directors up to 1% of the company's net profits.
Dividend payment to be completed on or before August 21, 2026.
Re-appointment of Ms. Rajeshwari Datla as a Non-Executive Director confirmed by special resolution.
👀 What to Watch
Investors should monitor the quarterly disclosures to see how much of the ₹100 crore related party transaction limit is utilized for the US subsidiary's operations.
Fermenta Biotech Shareholders Approve Rs 3.75 Dividend at 74th AGM
Fermenta Biotech Limited concluded its 74th Annual General Meeting on August 11, 2026, with shareholders approving all proposed resolutions with overwhelming majorities. A key highlight is the approval of a Rs 3.75 per equity share dividend (75% of face value) for FY26. Shareholders also ratified the audited standalone and consolidated financial statements for the year ended March 31, 2026. Additionally, approval was granted for material related party transactions and the re-appointment of Ms. Rajeshwari Datla as a Non-Executive Director.
Confidence: HIGH
What changedThe proposed dividend and FY26 financial statements have transitioned from board recommendations to shareholder-approved mandates.
Why it mattersThe high approval rates (99.9%+) indicate strong shareholder confidence in the management and the company's financial reporting. The dividend confirms a cash outflow to shareholders, reflecting the company's capital allocation policy for the past fiscal year.
Dividend per share: Rs 3.75Dividend as % of Face Value: 75%Face Value per share: Rs 5Approval for Related Party Transactions: 99.9763%AGM Date: August 11, 2026
📅 Short termThe stock may see minor interest due to the formalization of the dividend payout, though this was likely already priced in following the initial board recommendation.
📈 Long termLimited structural impact as the AGM results are routine; however, the continued approval of related party transactions suggests ongoing operational dependencies that investors should monitor.
Key Highlights
Dividend of Rs 3.75 per equity share (75% of Rs 5 face value) approved for FY26.
Material Related Party Transactions resolution passed with 99.9763% votes in favor.
FY26 Standalone and Consolidated Financial Statements adopted with 99.9999% shareholder approval.
Re-appointment of Ms. Rajeshwari Datla as Director approved with 99.9980% majority.
AGM conducted virtually, concluding at 5:12 p.m. IST on August 11, 2026.
👀 What to Watch
Investors should track the upcoming record date and payment timeline for the approved Rs 3.75 dividend. Reviewing the details of the 'Material Related Party Transactions' in the annual report is recommended to understand the nature of these business dealings.
INR 126.2 Cr Revenue in Q1 FY27; Human Nutrition Grows 24% QoQ Despite 56% PAT Drop
Fermenta Biotech reported a weak YoY performance for Q1 FY27, with PAT falling 56% to INR 9.5 crore, largely due to a high base in Q1 FY26 which included non-recurring income. Revenue stood at INR 126.2 crore, down 13% YoY, though the Human Nutrition segment showed sequential recovery with 24% QoQ growth to INR 76.5 crore. The company is pivoting toward the domestic market, with India now contributing 47% of revenue compared to 35% a year ago. Animal nutrition remains a significant drag, with volumes down 52% QoQ as the company maintained volume discipline against a 40% drop in realizations.
Confidence: HIGH
What changedThe company has shifted its geographical focus toward India (47% of revenue) and is transitioning its product mix toward higher-value human nutrition and plant-based Vitamin D3.
Why it mattersThe shift helps mitigate volatility in the global animal nutrition market, though rising employee costs and lower realizations in animal feed are currently weighing on margins.
Q1 FY27 Revenue: INR 126.2 croreQ1 FY27 PAT: INR 9.5 croreHuman Nutrition QoQ Growth: 24%India Revenue Share: 47%Dahej Capex: INR 110 crore
📅 Short termThe stock may see negative pressure due to the sharp YoY decline in PAT and EBITDA, despite the sequential recovery in the human nutrition segment.
📈 Long termStructural growth depends on the successful ramp-up of the Dahej facility and the adoption of new products like Calcifediol and vegan Vitamin D3.
⚠ Risk flags
- Significant realization drop in Animal Nutrition (40% YoY)
- Rising employee cost intensity (19% of revenue)
- High base effect dependency
Key Highlights
Human Nutrition revenue grew 24% QoQ to INR 76.5 crore, with segment volumes increasing 18% QoQ.
Animal Nutrition revenue fell 41% YoY to INR 12.6 crore, impacted by a 40% drop in average realizations.
India's share of consolidated revenue increased to 47% in Q1 FY27 from 35% in Q1 FY26.
Raw material costs improved to 35% of revenue, down from 37% in FY26 and 38% in FY25.
Employee costs rose to 19% of revenue from 16% in FY26, reflecting capacity expansion ahead of Dahej scale-up.
👀 What to Watch
Monitor the commercialization timeline of Calcifediol at the Dahej facility and the market uptake of VITADEE Green following its FSSAI approval on July 6, 2026.
₹9.5 Cr PAT in Q1FY27; Human Nutrition Volumes Up 18% QoQ Despite 56% YoY Profit Drop
Fermenta Biotech reported a 56% YoY decline in consolidated Profit After Tax (PAT) to ₹9.5 crore for Q1FY27, primarily due to a high base in the previous year and a 40% drop in Vitamin D3 Animal Nutrition realizations. Consolidated revenue stood at ₹126.2 crore, down 13% YoY but flat sequentially. A key positive is the 18% sequential volume growth in the Human Nutrition segment and the recent FSSAI approval for VITADEE Green®. The company is also seeing a shift in geographical mix, with India now contributing 47% of revenue compared to 35% a year ago.
Confidence: HIGH
What changedFermenta reported a sharp decline in profitability compared to a high-base Q1FY26, while showing sequential volume recovery in human nutrition and securing a key regulatory approval for its plant-based Vitamin D3.
Why it mattersThe results highlight a strategic shift toward the domestic market and human nutrition to offset pricing volatility in the global animal nutrition market. The upcoming Dahej capacity for plant-based Vitamin D3 is critical for future margin expansion.
Consolidated Revenue (Q1FY27): ₹126.2 croreProfit After Tax (Q1FY27): ₹9.5 croreAnimal Nutrition Realization Change: -40% YoYHuman Nutrition Volume Growth: +18% QoQIndia Revenue Share: 47%Diluted EPS: Rs. 3.34
📅 Short termThe stock may face short-term pressure due to the significant YoY decline in PAT and EBITDA, although sequential stability in revenue provides some support.
📈 Long termThe long-term outlook depends on the successful scaling of the Dahej plant and the adoption of plant-based Vitamin D3 (VITADEE Green®) in the Indian market.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Severe pricing pressure in Animal Nutrition (40% realization drop)
- Losses in German and US subsidiaries
- Execution risk for new capacity at Dahej
Key Highlights
Consolidated PAT fell 56% YoY to ₹9.5 crore, impacted by a 40% drop in Animal Nutrition realizations.
Human Nutrition volumes grew 18% sequentially, with the segment contributing ₹76.5 crore to revenue.
India's share of consolidated revenue increased to 47% from 35% in the previous year.
VITADEE Green® received FSSAI approval on July 6, 2026, for use in health supplements and food fortification.
Consolidated EBITDA (including real estate) was ₹22.4 crore, down 39% YoY and 11% QoQ.
👀 What to Watch
Monitor the commercialization timeline of the Dahej plant for plant-based Vitamin D3 and the market uptake of VITADEE Green® following FSSAI approval. Investors should also watch for stabilization in Animal Nutrition pricing, which remains a significant drag on margins.
Fermenta Biotech Approves Q1 FY27 Unaudited Financial Results
Fermenta Biotech Limited's Board of Directors met on August 11, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The statutory auditors, M/s. SRBC & Co. LLP, issued a limited review report with an unmodified opinion, suggesting no significant accounting irregularities were identified. The board meeting lasted 2 hours and 10 minutes. While the specific P&L figures were not detailed in this cover letter, the filing confirms the completion of the mandatory quarterly reporting cycle.
Confidence: HIGH
What changedThe company has completed its formal board approval and auditor review for the Q1 FY27 reporting period.
Why it mattersQuarterly earnings are the primary tool for investors to assess the company's operational performance and financial stability in the pharmaceutical sector.
Quarter ended: June 30, 2026Meeting duration: 2 hours 10 minutesAudit opinion type: Unmodified3-month price return: 82.8%
📅 Short termThe stock price may react to the specific revenue and profit figures contained in the full results attachment, which were not summarized in this cover letter.
📈 Long termLimited; this is a routine quarterly regulatory filing.
Key Highlights
Board approved unaudited standalone and consolidated results for the quarter ended June 30, 2026
Statutory auditors SRBC & Co. LLP issued an unmodified opinion on the financial results
Board meeting commenced at 11:00 a.m. and concluded at 01:10 p.m. on August 11, 2026
The filing was made pursuant to Regulations 30 and 33 of SEBI Listing Regulations
👀 What to Watch
Investors should examine the full financial tables (specifically revenue and OPM) to understand if the recent 82.8% 3-month price rally is supported by fundamental earnings growth.
